Chris Bostick

Chris Bostick


Chris is passionate about technologies using interdisciplinary approaches to enable precision medicine.

He focuses on healthcare investments at OCV and Co-led investments including Praxis Precision Medicines, Finch Therapeutics, Rad AI, and Precision Biosciences. Most recently he was recognized by Biocom in 2021 as one of ten life science trailblazers under 40. Prior to OCV Dr. Bostick completed postdoctoral work at the Institute for Genomic Medicine at Columbia University where he studied precision medicine-based approaches for treating genetic neurological disorders. Prior to that he did research for his Ph.D. in drug metabolism, bioelectronics/biosensors, and nanotechnology. Dr. Bostick holds a B.S. in Biology with a minor in Business from Cornell University and a Ph.D. in Pharmacological and Pharmaceutical Sciences from West Virginia University where he was an NSF IGERT Fellow.

Chris serves as a Board Member for the following portfolio companies:

  • Rad AI
  • Ossio (Observer)
  • TORL (Observer)

With our decades of company building experience, we look to create asymmetric advantages when backing winning teams.